update on clinical trials, page-3

Yes, Vagiv Soultanov is an amazing guy, and it appears Solagran's research is close to hitting paydirt.

The 'alternative' tag applied to some of Soultanov's ideas might trouble some readers (a bed of nails???) but remember, inspiration may come from any number of sources. What's critical is whether, when tested objectively, ideas stack up in the real world. After all, even Sir Isaac Newton, the paragon of empirical logic, was an alchemist on his days off! And that old apple muncher is not remembered for his attempts at transmutation of metals!

The Phase II Trial of Bioeffective R will be completed shortly. With preliminary results already pointing to Bioeffective R’s being superior to one of the world's most widely-used hepatoprotective preparations, Essentiale Forte AND a manufacturing agreement with Galenopharm, one of Russia’s leading pharmaceutical manufacturers already in place (Galenopharm has been involved with Solagran throughout its clinical trials program and will produce Ropren – the finished form version of Bioeffective R – for the Russian market, once regulatory approval has been granted) I’d suggest that Solagran is an investment idea whose time has come!

Time will tell.